At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
RHH646 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating RHH646 and Placebo for Osteoarthritis, Knee. Completed, enrolled 82 participants across 10 sites in 5 countries.
Detailed Summary
The purpose of this study was to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesArgentina, Denmark, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedApr 2023
Enrollment StartMay 2023
Primary CompletionFeb 2025
TodayJul 2026
First PostedApr 18, 2023
Enrollment StartMay 31, 2023
Primary CompletionFeb 24, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.2 years ago
Interventions
RHH646drug
RHH646 capsule for oral use
Placebodrug
RHH646 placebo capsule for oral use